Literature DB >> 17363507

Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis.

Jing Wang1, Karen Kuropatwinski, Jennie Hauser, Michael R Rossi, Yunfei Zhou, Alexis Conway, Julie L C Kan, Neil W Gibson, James K V Willson, John K Cowell, Michael G Brattain.   

Abstract

PIK3CA, encoding the p110alpha catalytic subunit of phosphatidylinositol 3-kinase (PI3K), is mutated in a variety of human cancers. We screened the colon cancer cell lines previously established in our laboratory for PIK3CA mutations and found that four of them harbored gain of function mutations. We have now compared a panel of mutant and wild-type cell lines for cell proliferation and survival in response to stress. There was little difference in PI3K activity between mutant PIK3CA-bearing cells (mutant cells) and wild-type PIK3CA-bearing cells (wild-type cells) under optimal growth conditions. However, the mutant cells showed constitutive PI3K activity during growth factor deprivation stress (GFDS), whereas PI3K activity decayed rapidly in the wild-type cells. Importantly, constitutively active PI3K rendered the mutant cells resistant to GFDS-induced apoptosis relative to the wild-type cells, indicating a biological advantage under stress conditions that is imparted by the mutant enzymes. Compared with the wild-type cells, the mutant cells were hypersensitive to the apoptosis induced by the PI3K inhibitor LY294002. In addition, PIK3CA small interfering RNA significantly decreased DNA synthesis and/or induced apoptosis in the mutant cells but not in the wild-type cells. Furthermore, ecotopic expression of a mutant PIK3CA in a nontumorigenic PIK3CA wild-type cell line resulted in resistance to GFDS-induced apoptosis, whereas transfection of wild-type PIK3CA or empty vector had little effect. Taken together, our studies show that mutant PIK3CA increases the capacity for proliferation and survival under environmental stresses, such as GFDS while also imparting greater dependency on the PI3K pathway for proliferation and survival.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17363507     DOI: 10.1158/1535-7163.MCT-06-0555

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  24 in total

1.  Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor.

Authors:  Yi Peter Hu; Sandip B Patil; Michelle Panasiewicz; Wenhui Li; Jennie Hauser; Lisa E Humphrey; Michael G Brattain
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

2.  Restoration of PTEN activity decreases metastases in an orthotopic model of colon cancer.

Authors:  Sanjib Chowdhury; Melanie Ongchin; Guanghua Wan; Elizabeth Sharratt; Michael G Brattain; Ashwani Rajput
Journal:  J Surg Res       Date:  2013-04-06       Impact factor: 2.192

3.  TGFβ and IGF1R signaling activates protein kinase A through differential regulation of ezrin phosphorylation in colon cancer cells.

Authors:  Premila D Leiphrakpam; Michael G Brattain; Jennifer D Black; Jing Wang
Journal:  J Biol Chem       Date:  2018-03-29       Impact factor: 5.157

4.  Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib.

Authors:  John J Arcaroli; Kevin S Quackenbush; Rebecca W Powell; Todd M Pitts; Anna Spreafico; Marileila Varella-Garcia; Lynne Bemis; Aik Choon Tan; Jaclyn M Reinemann; Basel M Touban; Arvind Dasari; S Gail Eckhardt; Wells A Messersmith
Journal:  Clin Cancer Res       Date:  2012-05-01       Impact factor: 12.531

5.  Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines.

Authors:  Laetitia Dahan; Amine Sadok; Jean-Louis Formento; Jean François Seitz; Hervé Kovacic
Journal:  Br J Pharmacol       Date:  2009-09       Impact factor: 8.739

Review 6.  Mechanisms of tumor resistance to EGFR-targeted therapies.

Authors:  Elizabeth A Hopper-Borge; Rochelle E Nasto; Vladimir Ratushny; Louis M Weiner; Erica A Golemis; Igor Astsaturov
Journal:  Expert Opin Ther Targets       Date:  2009-03       Impact factor: 6.902

7.  Ezrin expression and cell survival regulation in colorectal cancer.

Authors:  Premila D Leiphrakpam; Ashwani Rajput; Michelle Mathiesen; Ekta Agarwal; Audrey J Lazenby; Chandrakanth Are; Michael G Brattain; Sanjib Chowdhury
Journal:  Cell Signal       Date:  2014-01-22       Impact factor: 4.315

8.  PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.

Authors:  Minaxi Jhawer; Sanjay Goel; Andrew J Wilson; Cristina Montagna; Yi-He Ling; Do-Sun Byun; Shannon Nasser; Diego Arango; Joongho Shin; Lidija Klampfer; Leonard H Augenlicht; Roman Perez-Soler; Roman Perez Soler; John M Mariadason
Journal:  Cancer Res       Date:  2008-03-15       Impact factor: 12.701

9.  Knockdown of Ron kinase inhibits mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma.

Authors:  Jing Wang; Ashwani Rajput; Julie L C Kan; Rebecca Rose; Xiao-Qiong Liu; Karen Kuropatwinski; Jennie Hauser; Alexander Beko; Ivan Dominquez; Elizabeth A Sharratt; Lisa Brattain; Charles Levea; Feng-Lei Sun; David M Keane; Neil W Gibson; Michael G Brattain
Journal:  J Biol Chem       Date:  2009-02-18       Impact factor: 5.157

10.  Prognostic and therapeutic implications of NHERF1 expression and regulation in colorectal cancer.

Authors:  Premila D Leiphrakpam; Audrey J Lazenby; Sanjib Chowdhury; Lynette M Smith; Michelle Mathiesen; Michael G Brattain; Jing Wang; Jennifer D Black; Chandrakanth Are
Journal:  J Surg Oncol       Date:  2019-12-22       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.